The financials
Travere Therapeutics, Inc. by the numbers
Travere Therapeutics, Inc. (TVTX) reported revenue of $170M in Q2 2026 (quarter ended June 30, 2026), up 48% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $35M. For the full year FY2025, revenue was $491M (+110% year on year) and net income −$26M. Its largest product in 2026-Q1 was FILSPARI at $105M, 83% of the disclosed total, just ahead of Tiopronin Products at 15%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $170M | $114M | +48% |
| Gross profit | $167M | $113M | +48% |
| Operating income | $4.0M | −$13M | to a profit |
| Net income | −$35M | −$13M | n/a |
| Diluted EPS | −$0.37 | −$0.14 | n/a |
| Product | Revenue | Share |
|---|---|---|
| FILSPARI | $105M | 83% |
| Tiopronin Products | $19M | 15% |
| License | $2.7M | 2.1% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $127.2M (-39%)
FILSPARI grew +88% year on yearLicense -54% year on year
Segment Latestquarter on quarteryear on year
- FILSPARI$105.2M$105.2MQoQ +16%year on year +88%+16%+88%
- Tiopronin Products$19.3M$19.3MQoQ -13%year on year -3.2%-13%-3.2%
- License$2.7M$2.7MQoQ -95%year on year -54%-95%-54%
- License And Collaboration Clinical Development Activities--QoQ -year on year ---
- License And Collaboration Sale Of Pharmaceutical Ingredients--QoQ -year on year ---
- Market Access Milestone--QoQ -year on year ---
- Royalty--QoQ -year on year ---